Comparison
5p Partial Monosomy Syndrome C0010314 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between 5P Partial Monosomy Syndrome and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
5p Partial Monosomy Syndrome C0010314
Also called Cri-du-chat syndrome, caused by a deletion on chromosome 5. Features include a high-pitched cry, developmental delay, and intellectual disability.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
5p Partial Monosomy Syndrome C0010314
0-0
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
5p Partial Monosomy Syndrome C0010314
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
5p Partial Monosomy Syndrome C0010314
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
5p Partial Monosomy Syndrome C0010314
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
5p Partial Monosomy Syndrome C0010314
congenital
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
5p Partial Monosomy Syndrome C0010314
genetic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
5p-partial-monosomy-syndrome-C0010314 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5p Partial Monosomy Syndrome C0010314 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| High-pitched cry | Characteristic neonatal cry is described in Cri-du-chat syndrome. | Not a described feature of 2-hydroxyglutarate aciduria. | High |
| Neurodevelopmental effects | Developmental delay and intellectual disability are typical. | Brain and nervous-system involvement may occur, but the pattern is not established here. | Moderate |
| Metabolic accumulation | No described accumulation of 2-hydroxyglutaric acid. | Buildup of 2-hydroxyglutaric acid defines the metabolic disorder. | High |
When to favor each condition
Choose 5p Partial Monosomy Syndrome C0010314 when
Congenital features with a high-pitched cry
This pattern points toward a chromosome 5 deletion rather than a metabolic aciduria.
High
Suspected chromosomal cause
The supplied etiology is genetic deletion, not metabolite accumulation.
High
Severe congenital presentation
The source classifies this condition as severe, but individual severity still needs clinical assessment.
Moderate
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Evidence of organic-acid accumulation
2-hydroxyglutaric acid buildup supports the metabolic diagnosis over a chromosomal deletion.
High
Childhood-onset neurologic concern
The supplied onset range extends through childhood, unlike the congenital onset listed for the left condition.
Moderate
Need for metabolic monitoring
Management is described as supportive with monitoring for complications.
Moderate
How key tests differ
| Test | 5p Partial Monosomy Syndrome C0010314 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Chromosomal testing | May identify a deletion involving chromosome 5. | Not expected to establish 2-hydroxyglutarate aciduria. | A positive chromosomal result supports the left diagnosis; absence does not exclude other conditions. |
| Urine organic-acid analysis | No specific 2-hydroxyglutaric acid abnormality is described. | May show elevated 2-hydroxyglutaric acid; exact cutoffs are not supplied. | An abnormal result is not itself a complete diagnosis and requires clinician interpretation. |
| Neurologic assessment | May document developmental delay or intellectual disability. | May identify brain or nervous-system effects when present. | Findings overlap and cannot reliably distinguish the conditions alone. |
Prognosis comparison
5p Partial Monosomy Syndrome C0010314
- Outcome
- A chronic, potentially severe congenital course is described; exact outcomes are not established.
- Factors
- Deletion-related developmental and intellectual effects may influence needs.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- A chronic metabolic course of moderate listed severity is described; outcomes vary.
- Factors
- Neurologic involvement and response to supportive monitoring may influence course.
Time frame: Lifelong or long-term follow-up may be needed; precise timelines are not established.
Individual findings, complications, and clinician assessment determine prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Developmental delay and intellectual disability are described. Neurologic effects may occur, but specific deficits are not established here. Both may need developmental support; the exact burden varies. |
| Neurologic complications | Not specifically detailed beyond developmental and intellectual effects. Brain and nervous-system involvement is possible. Monitoring is appropriate, especially for the metabolic condition. |
| Long-term care needs | Severe congenital course may require ongoing multidisciplinary care. Supportive therapy and complication monitoring are described. Care plans should be individualized; no treatment doses are established here. |
Patient education highlights
- HighDifferent causes
One condition is a chromosome 5 deletion; the other involves buildup of 2-hydroxyglutaric acid.
- HighTesting limits
An abnormal laboratory result should be interpreted by a clinician and does not automatically confirm a diagnosis.
- MediumSupportive care
Management is individualized. No specific doses or outcome guarantees are provided by this comparison.